← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
trastuzumab emtansine
L01FD03
Forms & Strengths
- Lyophilized powder for injection: 100 mg per single-dose vial
- Lyophilized powder for injection: 160 mg per single-dose vial
Adult Dosing
- HER2-positive metastatic breast cancer: 3.6 mg/kg intravenously every 3 weeks (21-day cycle)
- HER2-positive early breast cancer (adjuvant): 3.6 mg/kg intravenously every 3 weeks for a total of 14 cycles
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Adjuvant treatment of HER2-positive early breast cancer in patients who have residual invasive disease after preoperative taxane-based and trastuzumab-based therapy
- Treatment of HER2-positive metastatic breast cancer in patients who previously received trastuzumab and a taxane (individually or in combination)
Mechanism of Action
- Antibody-drug conjugate (ADC) consisting of trastuzumab (humanized anti-HER2 IgG1) covalently linked to DM1 (a mertansine tubulin inhibitor via a stable thioether linker)
- Binds to HER2-expressing tumor cells, undergoes receptor-mediated internalization, and releases DM1-containing catabolites to inhibit microtubule assembly and induce cell cycle arrest and apoptosis
Contraindications
- Severe hypersensitivity to trastuzumab, emtansine, or murine proteins
- Severe hypersensitivity to any components of the formulation
Adverse Reactions
- Hepatotoxicity (elevated AST/ALT, nodular regenerative hyperplasia, portal hypertension)
- Left ventricular dysfunction (decreased left ventricular ejection fraction)
- Interstitial lung disease, pneumonitis
- Peripheral neuropathy (predominantly sensory)
- Thrombocytopenia, hemorrhage, anemia
- Fatigue, nausea, musculoskeletal pain, headache
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) may increase exposure to DM1 and the risk of toxicity; avoid coadministration if possible
- Concomitant use with hepatotoxic drugs may exacerbate liver injury
Curated Content: Needs Vetting Before Put to Clinical Use